On Thursday, the U.S. Food and Drug Administration gave the green light to
a biologic medication that prevents or significantly delays the onset of
type 1 diabetes.
This is the first treatment to be given the green light for preventing type
1 diabetes.
Intravenous infusion of the monoclonal antibody teplizumab, developed by
ProventionBio and Sanofi and branded as Tzield, is the recommended method
of administration. The medicine producer announced on a Friday investor
call that the wholesale price of the therapy for an entire course of
treatment would be around $194,000. However, this price is not expected to
be paid by consumers.
a biologic medication that prevents or significantly delays the onset of
type 1 diabetes.
This is the first treatment to be given the green light for preventing type
1 diabetes.
Intravenous infusion of the monoclonal antibody teplizumab, developed by
ProventionBio and Sanofi and branded as Tzield, is the recommended method
of administration. The medicine producer announced on a Friday investor
call that the wholesale price of the therapy for an entire course of
treatment would be around $194,000. However, this price is not expected to
be paid by consumers.
